US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Eikon Therapeutics (EIKN): Merck Alumni Lead Late-Stage Immuno-Oncology IPO Candidate

Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

IPOs and Secondary Offerings

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Disappointing Debut: Eikon Therapeutics priced an upsized IPO at $18.00 but opened down 5.3% and closed at $15.00, never approaching issue price.</li>
<li>Demand Disconnect: Despite ~6x oversubscription and high-end pricing, weak aftermarket support exposed a mismatch between bookbuilding strength and true buy-side demand.</li>
<li>Sector Reminder: The deal marks the worst biotech IPO performance of 2025–2026, highlighting ongoing volatility and selective risk appetite across late-stage biotech offerings.</li>
</ul>


Disappointing Debut: Eikon Therapeutics priced an upsized IPO at $18.00 but opened down 5.3% and closed at $15.00, never approaching issue price.
Demand Disconnect: Despite ~6x oversubscription and high-end pricing, weak aftermarket support exposed a mismatch between bookbuilding strength and true buy-side demand.
Sector Reminder: The deal marks the worst biotech IPO performance of 2025–2026, highlighting ongoing volatility and selective risk appetite across late-stage biotech offerings.


에이콘 테라퓨틱스(EIKN): 후기 임상 단계 면역항암제 IPO, 가격은 강세를 보였으나 데뷔전에서 실패